ANGIOGENIC & TISSUE RESEARCH

KPV: Anti-Inflammatory Tripeptide in Preclinical Research

Velox Peptides Research Team·Published May 2026·5 min read
CAS Number
13147-97-2
Sequence
Lys-Pro-Val
Origin
C-terminal α-MSH fragment
HPLC Purity
≥98.5% (batch-verified)
For in vitro research use only. KPV is supplied solely as a research reagent for in vitro use and is not for human or veterinary consumption.

What is KPV?

KPV is a tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). Although it is only three amino acids long, this fragment retains much of the anti-inflammatory activity associated with the larger parent peptide, while lacking its pigmentary (melanocortin-receptor) effects.

This combination — anti-inflammatory activity without the pigmentation signalling of full α-MSH — is what makes KPV a focused research tool for studying inflammation pathways.

NF-κB inhibition and mucosal inflammation models

NF-κB pathway. The most studied property of KPV in preclinical models is its association with inhibition of NF-κB signalling — a master regulator of inflammatory gene expression. By dampening this pathway, KPV is studied for its association with reduced production of pro-inflammatory mediators in cell and animal models.

Gut and mucosal research. KPV has been studied particularly in models of intestinal and mucosal inflammation, where research has examined its uptake by epithelial cells and its association with reduced inflammatory markers in the gut.

Research context

KPV sits within the angiogenic & tissue research category, where it is studied alongside tissue-repair peptides such as BPC-157 and TB-500 that engage complementary repair and anti-inflammatory pathways.

Velox Peptides supply information

Velox Peptides supplies KPV as a lyophilised powder at ≥98.5% HPLC-verified purity with a batch certificate of analysis available on request. For reconstitution, see the reconstitution calculator. Supplied strictly as a research reagent for in vitro use.

References & further reading

  1. Luger TA, Brzoska T. “alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.” Annals of the Rheumatic Diseases, 2007.
  2. Dalmasso G et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology, 2008.

Summaries are paraphrased from the peer-reviewed literature. For full source citations, email veloxpeps@gmail.com.

Frequently asked questions

What is KPV?
KPV is a tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment of alpha-MSH, studied for anti-inflammatory activity. Velox Peptides supplies it as a research reagent for in vitro use only.
What pathway is KPV associated with?
In preclinical models KPV is most associated with inhibition of the NF-kB inflammatory signalling pathway, particularly in mucosal and intestinal models.
What purity is Velox Peptides KPV?
KPV is HPLC-verified at a minimum of 98.5% purity, with batch documentation available on request.
Is KPV legal to buy in the UK?
Yes — for in vitro research purposes. Velox Peptides supplies it solely as a research reagent, not for human or veterinary use.
Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.

All research summaries on this page are derived from publicly available peer-reviewed literature. Velox Peptides makes no therapeutic claims. For research use only.